Previous 10 | Next 10 |
Third quarter 2022 sales of $2.1 billion, up 2%, or 9% constant currency (cc) Third quarter 2022 earnings were $0.23 per diluted share; core earnings of $0.50 per diluted share, down 7%, or up 14% cc Updated 2022 outlook reflects strong sales growth and operational l...
Alcon ( NYSE: ALC ) is scheduled to announce Q3 earnings results on Tuesday, November 15th, after market close. The consensus EPS Estimate is $0.49 (-9.3% Y/Y) and the consensus Revenue Estimate is $2.13B (+2.4% Y/Y). Over the last 2 years, ALC has beaten EPS estimat...
Summary Several long-standing biopharmaceutical holdings drove performance. An unprecedented set of global challenges makes it more important than ever to own cash-generative businesses with strong balance sheets that can take advantage of dislocations in the market and the econom...
Summary Weakness in the Strategy’s consumer discretionary and technology names and underweights to several outperforming mega cap growth stocks weighed on performance relative to the benchmark. Weakness in the Strategy’s consumer discretionary and technology names an...
Highlighting latest clinical findings, including comparative efficacy for ocular itch relief between Pataday Once Daily Relief Extra Strength and an oral antihistamine Forthcoming innovations in eye care to be previewed, including TOTAL30 for Astigmatism TOTAL po...
Founded in 1945 and based in Switzerland, Alcon AG (ALC) is a global provider of ophthalmic surgery and vision care products; previously a subsidiary of Novartis AG (NVS), Alcon became an independent company in April, 2019, recalls Jasper Hellweg, an analyst with Argus Research. For further...
Clareon Toric, a glistening-free * toric intraocular lens with exceptional clarity and unrivaled stability, is rolling out across select practices in the U.S. 1-5 Alcon digital innovations, including the newly available Fidelis Virtual Reality Ophthalmic Surgical Sim...
Summary A high level of restructuring is occurring with the Healthcare industry’s largest constituents. Most restructuring is taking the form of splits or spin-offs, but not all incidences look beneficial. This article will summarize coming transactions and provide comm...
Summary Alcon has continued in a downtrend since September 2021 with persistent mean reversion activity across this time. With FY22 guidance narrowed and macro-headwinds prevailing, forward-looking multiples are less attractive to peers. We see a value gap to the downside in A...
Alcon (NYSE: ALC) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has announced entry into a definitive merger agreement where Alcon will acquire Aerie. Alcon will add commercial products Rocklatan and Rhopressa and a pipeline of several clinical and preclinical o...
News, Short Squeeze, Breakout and More Instantly...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Alcon Inc. (NYSE: ALC) traded at a new 52-week high today and are currently trading at $91.69. So far today, approximately 136.09k shares have been exchanged, as compared to an average 30-day volume of 907.93k shares. Alcon Inc., an eye care company, researches, develops, manufactur...